AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Mefexamide hydrochloride is believed to exert its effects by acting as a muscle relaxant, potentially reducing muscle spasms and stiffness.
Central Nervous System (CNS) Effects: Like other muscle relaxants, mefexamide hydrochloride may have central nervous system effects. These can include drowsiness, dizziness, and sedation. Patients taking mefexamide hydrochloride should be cautious when operating machinery or driving until they understand how the medication affects them.
Adverse Reactions: While specific adverse reactions associated with mefexamide hydrochloride may vary, common side effects of muscle relaxants in general can include nausea, vomiting, headache, blurred vision, dry mouth, and constipation.
Drug Interactions: Mefexamide hydrochloride may interact with other medications, including other muscle relaxants, opioids, benzodiazepines, and alcohol. Patients should inform their healthcare providers about all medications they are taking to avoid potential interactions.
Contraindications: Mefexamide hydrochloride may be contraindicated in individuals with certain medical conditions, such as myasthenia gravis, liver disease, or kidney disease. It is important for healthcare providers to review a patient's medical history thoroughly before prescribing mefexamide hydrochloride.
Pregnancy and Lactation: There may be limited data available on the safety of mefexamide hydrochloride use during pregnancy and breastfeeding. Pregnant or breastfeeding individuals should consult their healthcare provider before taking this medication.
Discontinuation: As with any medication, mefexamide hydrochloride should be discontinued gradually under the guidance of a healthcare provider to avoid potential withdrawal symptoms or rebound effects.
Monitoring: Patients taking mefexamide hydrochloride may require monitoring for effectiveness and potential side effects, especially during the initial stages of treatment or when adjusting the dosage.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.2 | -0.2 | |
ADHD | 2.5 | 2.5 | |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.1 | 3 |
Allergic Rhinitis (Hay Fever) | 0.8 | 1 | -0.25 |
Allergies | 3.4 | 1.1 | 2.09 |
Allergy to milk products | 1.1 | 0.6 | 0.83 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 2.4 | 2.6 | -0.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 1.1 | 0.91 |
Ankylosing spondylitis | 2.5 | 0.5 | 4 |
Anorexia Nervosa | 0.1 | 1.2 | -11 |
Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
Asthma | 0.3 | 1.2 | -3 |
Atherosclerosis | 0.7 | 1.1 | -0.57 |
Atrial fibrillation | 1.6 | 0.8 | 1 |
Autism | 4.1 | 4.4 | -0.07 |
Barrett esophagus cancer | 0.5 | 0.2 | 1.5 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.7 | 0.7 | 0 |
Brain Trauma | 0.4 | 0.5 | -0.25 |
Carcinoma | 2 | 1.6 | 0.25 |
Celiac Disease | 1.5 | 2.3 | -0.53 |
Cerebral Palsy | 1 | 0.9 | 0.11 |
Chronic Fatigue Syndrome | 2.1 | 2.9 | -0.38 |
Chronic Kidney Disease | 0.7 | 0.6 | 0.17 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0.3 | 3.33 |
Chronic Urticaria (Hives) | 1.5 | 0.8 | 0.88 |
Coagulation / Micro clot triggering bacteria | 1.2 | 0.9 | 0.33 |
Colorectal Cancer | 3.2 | 0.4 | 7 |
Constipation | 0.6 | 0.6 | 0 |
Coronary artery disease | 0.3 | 0.7 | -1.33 |
COVID-19 | 6.9 | 6.6 | 0.05 |
Crohn's Disease | 4.5 | 2.8 | 0.61 |
cystic fibrosis | 0.9 | 0.7 | 0.29 |
deep vein thrombosis | 0.9 | 0.5 | 0.8 |
Depression | 5.8 | 4.4 | 0.32 |
Dermatomyositis | 0.2 | 0.2 | 0 |
Eczema | 0.6 | 1.2 | -1 |
Endometriosis | 2.1 | 0.7 | 2 |
Eosinophilic Esophagitis | 0.2 | 0.3 | -0.5 |
Epilepsy | 2.3 | 1.8 | 0.28 |
Fibromyalgia | 1.7 | 0.7 | 1.43 |
Functional constipation / chronic idiopathic constipation | 3 | 2 | 0.5 |
gallstone disease (gsd) | 1.5 | 0.6 | 1.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.9 | 0 |
Generalized anxiety disorder | 1.5 | 1 | 0.5 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.7 | 1 | -0.43 |
Halitosis | 0.7 | 0.2 | 2.5 |
Hashimoto's thyroiditis | 1.5 | 0.4 | 2.75 |
Hidradenitis Suppurativa | 0.3 | 0.3 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2 | 0.4 | 4 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.5 | -0.25 |
hyperglycemia | 0.3 | 1.6 | -4.33 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.2 | 2 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.5 | 3.2 | -1.13 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 1.2 | -1.2 | |
Inflammatory Bowel Disease | 2.9 | 3.6 | -0.24 |
Insomnia | 0.8 | 0.6 | 0.33 |
Intelligence | 0.3 | 0.3 | |
Intracranial aneurysms | 0.8 | 0.2 | 3 |
Irritable Bowel Syndrome | 3.3 | 2.3 | 0.43 |
Liver Cirrhosis | 2.9 | 1.8 | 0.61 |
Long COVID | 3.7 | 4.3 | -0.16 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 1 | 1 | 0 |
ME/CFS with IBS | 0.3 | 1.4 | -3.67 |
ME/CFS without IBS | 0.5 | 1.1 | -1.2 |
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 5.1 | 4.8 | 0.06 |
Mood Disorders | 7.4 | 4.4 | 0.68 |
multiple chemical sensitivity [MCS] | 1 | 0.4 | 1.5 |
Multiple Sclerosis | 3 | 2 | 0.5 |
Multiple system atrophy (MSA) | 1.7 | 0.6 | 1.83 |
Neuropathy (all types) | 0.8 | 0.3 | 1.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 3.1 | -1.21 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 5 | 2.9 | 0.72 |
obsessive-compulsive disorder | 4.2 | 1.6 | 1.63 |
Osteoarthritis | 1.3 | 0.1 | 12 |
Osteoporosis | 1.1 | 1 | 0.1 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 2 | 2.1 | -0.05 |
Polycystic ovary syndrome | 1.2 | 1.2 | 0 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.2 | -1 |
Premenstrual dysphoric disorder | 0.8 | 0.1 | 7 |
primary biliary cholangitis | 0.2 | 0.4 | -1 |
Psoriasis | 3.3 | 1.2 | 1.75 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.2 | 2.3 | 0.39 |
Rosacea | 0.3 | 0.4 | -0.33 |
Schizophrenia | 3.5 | 1.1 | 2.18 |
scoliosis | 0.2 | -0.2 | |
Sjögren syndrome | 2.1 | 1.6 | 0.31 |
Sleep Apnea | 0.8 | 0.9 | -0.13 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.4 | 1.25 |
Stress / posttraumatic stress disorder | 2.1 | 1.4 | 0.5 |
Systemic Lupus Erythematosus | 2.3 | 1.2 | 0.92 |
Tic Disorder | 0.3 | 0.6 | -1 |
Tourette syndrome | 0.2 | 0.2 | 0 |
Type 1 Diabetes | 2.2 | 1 | 1.2 |
Type 2 Diabetes | 4.9 | 3.9 | 0.26 |
Ulcerative colitis | 2.3 | 2.5 | -0.09 |
Unhealthy Ageing | 2.1 | 0.9 | 1.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.